Vasodilatory mechanisms of beta receptor blockade.
Beta-blockers are widely prescribed for the treatment of a variety of cardiovascular pathologies. Compared to traditional beta-adrenergic antagonists, beta-blockers of the new generation exhibit ancillary properties such as vasodilation through different mechanisms. This translates into a more favorable hemodynamic profile. The relative affinities of beta-adrenoreceptor antagonists towards the three beta-adrenoreceptor isotypes matter for predicting their functional impact on vasomotor control. This review will focus on the mechanisms underlying beta-blocker-evoked vasorelaxation with a specific emphasis on agonist properties of beta(3)-adrenergic receptors.
Pole de Pharmacologie et Thérapeutique (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, B01.5309, Avenue Mounier 52, 1200, Brussels, Belgium. geraldine.rath@uclouvain.be
Géraldine
G
Rath
Jean-Luc
JL
Balligand
Chantal
C
Dessy
Dessy
D
Chantal
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001578:Benzopyrans / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects*; D004983:Ethanolamines / Q000494:pharmacology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000473:pathology; D000068577:Nebivolol; D011943:Receptors, Adrenergic, beta / Q000187:drug effects*; D014664:Vasodilation / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D011943:Receptors, Adrenergic, beta; D000068577:Nebivolol